The MarketReader Minute
π Intellia Inc's Performance Driven by Gene Editing Advances, Moderna Inc Impacted by RSV's low efficacy rates | Biotech Sector Insights
Moderna Inc's stock price decline was due to concerns about the effectiveness of its RSV shot at 18 and 24 months. This coincided with a decrease in the Russell 2000 Index by -0.41%, potentially impacting biotech stocks within the ETF's portfolio.